Detection of mutations in a gene associated with resistance to viral infection, mx1
AssigneeCubist Pharmaceuticals, Inc.
InventorsCharles L. Magness, Shawn P. Iadonato, Christina A. Scherer, Phillip Campion Fellin, Kathryn V. Steiger
Life of this patent
Estimating the term…
Abstract
A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided.
Claims23
A human genetic screening method comprising assaying a nucleic acid sample isolated from a human for the presence of an MxA gene mutation at nucleotide position 28459900, 28459935, 28460043, 28461329, 28461383, 28461516, 28465728, 28469610, 28469885, 28469924, 28469943, 28470658, 28470743, 28470915, 28474761, 28474878-28474906, 28475805-28475822, 28479224, 28479452, 28479482, 28479800, 28479976, 28480002, 28482983, 28483135, 28486319, 28486531, 28486603, 28486722, 28486744, 28492213, 28492295, 28492399, 28492560, 28492771-28492772, 28492948, 28474881, or 28474899 of SEQ ID NO:1.
An isolated protein encoded by a gene having at least one mutation at position 28459900, 28459935, 28460043, 28461329, 28461383, 28461516, 28465728, 28469610, 28469885, 28469924, 28469943, 28470658, 28470743, 28470915, 28474761, 28474878-28474906, 28475805-28475822, 28479224, 28479452, 28479482, 28479800, 28479976, 28480002, 28482983, 28483135, 28486319, 28486531, 28486603, 28486722, 28486744, 28492213, 28492295, 28492399, 28492560, 28492771-28492772, 28492948, 28474881, or 28474899 of SEQ ID NO:1.
A diagnostic for measuring resistance to viral infection.
A therapeutic compound for preventing or inhibiting infection by a virus, wherein said therapeutic compound is a protein encoded by the MxA gene.
A therapeutic compound for preventing or inhibiting infection by a virus, wherein the therapeutic compound is a protein encoded by an MxA gene having at least one mutation at position 28459900, 28459935, 28460043, 28461329, 28461383, 28461516, 28465728, 28469610, 28469885, 28469924, 28469943, 28470658, 28470743, 28470915, 28474761, 28474878-28474906, 28475805-28475822, 28479224, 28479452, 28479482, 28479800, 28479976, 28480002, 28482983, 28483135, 28486319, 28486531, 28486603, 28486722, 28486744, 28492213, 28492295, 28492399, 28492560, 28492771-28492772, 28492948, 28474881, or 28474899 of SEQ ID NO:1.
A therapeutic compound for preventing or inhibiting infection by a virus, wherein the therapeutic compound comprises any enzymatically active fragment of the protein encoded by the MxA gene. In a still further embodiment, the enzymatically active fragment may contain one or more of the mutations at position 28459900, 28459935, 28460043, 28461329, 28461383, 28461516, 28465728, 28469610, 28469885, 28469924, 28469943, 28470658, 28470743, 28470915, 28474761, 28474878-28474906, 28475805-28475822, 28479224, 28479452, 28479482, 28479800, 28479976, 28480002, 28482983, 28483135, 28486319, 28486531, 28486603, 28486722, 28486744, 28492213, 28492295, 28492399, 28492560, 28492771-28492772, 28492948, 28474881, or 28474899 of SEQUENCE 1. In a preferred embodiment, enzymatic activity is measured by GTP binding, GTP hydrolysis, homo-oligomerization, RNA binding, or virus polyprotein binding.
A therapeutic compound for preventing or inhibiting infection by a virus, wherein the therapeutic compound is a protein of the sequence:
- SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13.
23-32. (canceled)
Dependencies are inferred from the claim text.